Ranked #7,317 of 8,699 institutional investors
PSP Research LLC
Las Vegas, NV
$139M
US stock portfolio at live prices · today −$425K (−0.30%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $146M
- Change from Q2 2026
- −$42.1M (−22.38%)
- Positions
- 39 · 1 new, 27 sold out
- Filed
- Oct 21, 2026
Not counted in the ranking: none$1.3M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesSGOV 50.6%XBI 40.0%SERA 3.25%EXEL 0.24%TGTX 0.23%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| SGOV iShares 0-3 Month Treasury Bond ETF | 700,000 | $70.4M | 50.6% | Unchanged |
| XBI State Street SPDR S&P Biotech ETF | 386,500 | $55.7M | 40.0% | Reduced −32% |
| SERA Sera Prognostics, Inc. | 2,396,685 | $4.5M | 3.25% | New |
| EXEL Exelixis, Inc. | 5,000 | $329K | 0.24% | Reduced −38% |
| TGTX TG Therapeutics, Inc. | 5,000 | $324K | 0.23% | Reduced −50% |
| ORKA Oruka Therapeutics, Inc. | 3,000 | $293K | 0.21% | Unchanged |
| ARGX argenx SE | 300 | $283K | 0.20% | Reduced −53% |
| NBIX Neurocrine Biosciences, Inc. | 1,800 | $282K | 0.20% | Reduced −40% |
| HALO Halozyme Therapeutics, Inc. | 3,000 | $279K | 0.20% | Reduced −57% |
| TARS Tarsus Pharmaceuticals, Inc. | 3,500 | $272K | 0.20% | Reduced −50% |
| ARQT Arcutis Biotherapeutics, Inc. | 10,000 | $272K | 0.20% | Reduced −49% |
| STOK Stoke Therapeutics, Inc. | 9,000 | $242K | 0.17% | Reduced −25% |
| KYMR Kymera Therapeutics, Inc. | 2,000 | $239K | 0.17% | Reduced −50% |
| MIRM Mirum Pharmaceuticals, Inc. | 2,500 | $239K | 0.17% | Unchanged |
| MDGL Madrigal Pharmaceuticals, Inc. | 600 | $238K | 0.17% | Unchanged |
| INCY Incyte Corporation | 2,000 | $232K | 0.17% | Reduced −62% |
| HRMY Harmony Biosciences Holdings, Inc. | 7,000 | $231K | 0.17% | Reduced −30% |
| IMVT Immunovant, Inc. | 7,000 | $228K | 0.16% | Reduced −46% |
| TNGX Tango Therapeutics, Inc. | 10,000 | $227K | 0.16% | Unchanged |
| AUPH Aurinia Pharmaceuticals Inc. | 15,000 | $223K | 0.16% | Reduced −50% |
| KRYS Krystal Biotech, Inc. | 692 | $219K | 0.16% | Unchanged |
| DNTH Dianthus Therapeutics, Inc. | 2,500 | $212K | 0.15% | Unchanged |
| EWTX Edgewise Therapeutics, Inc. | 5,000 | $206K | 0.15% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 15,000 | $206K | 0.15% | Reduced −50% |
| IMNM Immunome, Inc. | 12,000 | $199K | 0.14% | Reduced −33% |
| DFTX Definium Therapeutics, Inc. | 6,500 | $192K | 0.14% | Reduced −35% |
| RVMD Revolution Medicines, Inc. | 1,200 | $191K | 0.14% | Unchanged |
| NTLA Intellia Therapeutics, Inc. | 20,000 | $190K | 0.14% | Unchanged |
| IMCR Immunocore Holdings plc | 7,000 | $186K | 0.13% | Reduced −54% |
| PTGX Protagonist Therapeutics, Inc. | 1,500 | $186K | 0.13% | Reduced −50% |
| NRIX Nurix Therapeutics, Inc. | 12,000 | $163K | 0.12% | Reduced −52% |
| DYN Dyne Therapeutics, Inc. | 10,000 | $160K | 0.12% | Reduced −50% |
| SNDX Syndax Pharmaceuticals, Inc. | 12,000 | $110K | <0.1% | Reduced −40% |
| ORIC ORIC Pharmaceuticals, Inc. | 13,000 | $100K | <0.1% | Unchanged |
| ARDX Ardelyx, Inc. | 30,000 | $92K | <0.1% | Reduced −50% |
| OCUL Ocular Therapeutix, Inc. | 15,000 | $88K | <0.1% | Unchanged |
| CMPS COMPASS Pathways plc | 10,000 | $87K | <0.1% | Reduced −44% |
| CTMX CytomX Therapeutics, Inc. | 39,400 | $81K | <0.1% | Unchanged |
| OLMA Olema Oncology, Inc. | 10,000 | $72K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| IRON Disc Medicine, Inc. | 8,000 | $609K |
| KOD Kodiak Sciences Inc. | 6,000 | $587K |
| SYRE Spyre Therapeutics, Inc. | 4,000 | $391K |
| CLDX Celldex Therapeutics, Inc. | 13,000 | $363K |
| PTCT PTC Therapeutics, Inc. | 6,000 | $350K |
| ACAD Acadia Pharmaceuticals Inc. | 19,766 | $348K |
| COGT Cogent Biosciences, Inc. | 12,000 | $333K |
| RAPP Rapport Therapeutics, Inc. | 14,000 | $330K |
| ELVN Enliven Therapeutics, Inc. | 7,000 | $325K |
| RARE Ultragenyx Pharmaceutical Inc. | 17,000 | $293K |
| AMLX Amylyx Pharmaceuticals, Inc. | 10,838 | $284K |
| LQDA Liquidia Corporation | 5,000 | $283K |
| ZYME Zymeworks Inc. | 10,000 | $269K |
| VKTX Viking Therapeutics, Inc. | 10,000 | $258K |
| BBIO BridgeBio Pharma, Inc. | 3,000 | $235K |
| RYTM Rhythm Pharmaceuticals, Inc. | 2,000 | $234K |
| ALNY Alnylam Pharmaceuticals, Inc. | 1,465 | $217K |
| GLUE Monte Rosa Therapeutics, Inc. | 23,000 | $205K |
| SRRK Scholar Rock Holding Corporation | 3,827 | $193K |
| VERA Vera Therapeutics, Inc. | 7,000 | $187K |
| IONS Ionis Pharmaceuticals, Inc. | 6,800 | $185K |
| XENE Xenon Pharmaceuticals Inc. | 4,200 | $158K |
| DNLI Denali Therapeutics Inc. | 8,463 | $154K |
| AXSM Axsome Therapeutics, Inc. | 1,000 | $136K |
| ARWR Arrowhead Pharmaceuticals, Inc. | 2,600 | $113K |
| AVBP ArriVent BioPharma, Inc. | 7,041 | $79K |
| EYPT EyePoint, Inc. | 10,000 | $3K |